Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events

[1]  K. Ohe,et al.  Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency. , 2020, European journal of cancer.

[2]  V. Prasad,et al.  Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs , 2020, JAMA network open.

[3]  James Clark,et al.  Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms , 2020, Immunology.

[4]  R. Uchi,et al.  Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. , 2019, Oral oncology.

[5]  Douglas B. Johnson,et al.  Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.

[6]  E. Sato,et al.  Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports , 2019, BMC Cancer.

[7]  Kazuhiko Yoshida,et al.  Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. , 2019, Urologic oncology.

[8]  Y. Nakamura.  Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events , 2019, Front. Med..

[9]  P. Conte,et al.  Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. , 2019, The oncologist.

[10]  David Bomze,et al.  Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. , 2019, European journal of cancer.

[11]  R. Sullivan,et al.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.

[12]  Y. Oda,et al.  Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade , 2018, Oncotarget.

[13]  G. Madonna,et al.  Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab , 2018, Journal of Immunotherapy for Cancer.

[14]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[15]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[16]  Y. Lou,et al.  Next generation of immune checkpoint therapy in cancer: new developments and challenges , 2018, Journal of Hematology & Oncology.

[17]  Y. Fujisawa,et al.  Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study , 2018, Oncotarget.

[18]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Matthew D. Hellmann,et al.  Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.

[20]  E. Jaffee,et al.  Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors , 2017, Oncotarget.

[21]  M. Suarez‐Almazor,et al.  Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group , 2017, Journal of Immunotherapy for Cancer.

[22]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[23]  Y. Fujisawa,et al.  Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab. , 2017, Journal of dermatological science.

[24]  D. Planchard,et al.  Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities , 2017, Journal of Crohn's & colitis.

[25]  Kaoru Tanaka,et al.  Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer , 2017, JAMA oncology.

[26]  W. Jochum,et al.  Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. , 2017, Lung cancer.

[27]  M. Wiese,et al.  Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers , 2017, British Journal of Cancer.

[28]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  C. Langer,et al.  Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. , 2017, Lung cancer.

[30]  H. Redmond,et al.  The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma , 2017, British Journal of Cancer.

[31]  J. Radford.  Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.

[32]  J. Lunceford,et al.  Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[34]  D. Hogg,et al.  The full blood count as a biomarker of outcome and toxicity in ipilimumab‐treated cutaneous metastatic melanoma , 2016, Cancer medicine.

[35]  C. Berking,et al.  Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab , 2016, Clinical Cancer Research.

[36]  J. Soria,et al.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review. , 2016, European journal of cancer.

[37]  D. Schadendorf,et al.  Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab , 2016, Clinical Cancer Research.

[38]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[39]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[40]  G. Gibney,et al.  Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes , 2015, Clinical Cancer Research.

[41]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[42]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  C. Ziegler,et al.  Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes , 2014, Cancer Immunology Research.

[44]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[45]  N. Kohno,et al.  Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. , 2012, Respiratory investigation.

[46]  N. Kohno,et al.  Circulating KL-6 levels in patients with drug induced pneumonitis , 2003, Thorax.

[47]  C. Baird.  The pilot study. , 2000, Orthopedic nursing.

[48]  Iris Xie,et al.  New developments and challenges , 2015 .